landogrozumab
mAbexperimental
Landogrozumab is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders. — Wikipedia
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT01524224)
Timeline
Indications
Mechanism of action
- Growth/differentiation factor 8INHIBITOR
MSTN inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLandogrozumab ↗
- ChEMBLCHEMBL3545072 ↗
Also known as
- landogrozumab
- landogrozumab
- ly2495655
- ly-2495655
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01604408 | Phase 2 | May 1, 2012 | Eli Lilly |
| NCT01505530 | Phase 2 | Dec 1, 2011 | Eli Lilly |
| NCT01369511 | Phase 2 | Jul 1, 2011 | Eli Lilly |
| NCT01341470 | Phase 1 | May 1, 2011 | Eli Lilly |
| NCT01524224 | Phase 1 | Jan 1, 2008 | Eli Lilly |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 5 | 5 | 2 | 2008 |
1 organizations
Page 1 / 1